The AMF has declared compliant the proposed simplified public tender offer (OPAS) for Biocorp shares, filed by Portzamparc (BNP Paribas group) and Lazard Frères Banque, on behalf of the Danish pharmaceutical company Novo Nordisk.

The offeror irrevocably undertakes to acquire, at a unit price of 35 euros, all the 1,094.726 shares that it does not hold, representing 24.81% of the share capital and 24.72% of the voting rights of this company.

Following the closing of the offer, and if the required conditions are met, the initiator intends to request the implementation of a squeeze-out for the Biocorp shares not tendered to the offer, at the same price.

Copyright (c) 2023 CercleFinance.com. All rights reserved.